Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Date of authorisation: 11/11/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Jentadueto, linagliptin,metformin hydrochloride, Date of authorisation: 19/07/2012, Revision: 25, Status: Authorised

CVMP recommendations on limited market classification and eligibility for authorisation under Article 23

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Foscan, temoporfin, Date of authorisation: 24/10/2001, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Fosavance, alendronic acid,colecalciferol, Date of authorisation: 24/08/2005, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Date of authorisation: 24/11/2025, Status: Authorised

Minutes of the PRAC meeting 24 - 27 November 2025

SPOR and XEVMPD status update webinar - Q1 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 28 January 2026, 10:00 (CET) to 28 January 2026, 12:30 (CET)

Human medicines European public assessment report (EPAR): Kapruvia, difelikefalin, Date of authorisation: 25/04/2022, Revision: 4, Status: Authorised